Spots Global Cancer Trial Database for [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer
Official Title: Phase 1b Exploratory Study of [18F]Fluciclatide-PET as a Marker of Angiogenic Response to Combination Therapy With the Pan-VEGF Inhibitor, Pazopanib, and Weekly Paclitaxel in Platinum Resistant Ovarian Cancer
Study ID: NCT01608009
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to assess \[18F\] -fluciclatide as a biomarker of response to pazopanib and to evaluate the efficacy and safety of the combination of pazopanib and paclitaxel in platinum-resistant ovarian cancer patients.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Imperial College Healthcare NHS Trust, London, , United Kingdom
Southend University Hospital NHS Foundation Trust, Southend, , United Kingdom
Contact Details
Name: Rohini Sharma, MD
Affiliation: Imperial College London
Role: STUDY_DIRECTOR
Name: Timothy Crook, MD
Affiliation: Southend University Hospital NHS Foundation Trust
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
